Pharvaris (PHVS) Cash from Investing Activities Growth (3y) (2023 - 2026)
Powered by 
Analysis
Pharvaris (PHVS) Cash from Investing Activities Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -44.69% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -39.73% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | -246.81% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -53.57% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 27.84% |
| 10 | Pharvaris | 2.14 Bn | 1.77 Bn | 85,072.10 | 99.19% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 99.19% |
| Mar 31, 2026 | -43.98% |
| Dec 31, 2025 | 57.97% |
| Sep 30, 2025 | -25.99% |
| Jun 30, 2025 | 25.99% |
| Mar 31, 2025 | -78.86% |
| Dec 31, 2024 | -29.92% |
| Sep 30, 2024 | 13,216.23% |
| Jun 30, 2024 | -13,819.64% |
| Mar 31, 2024 | -40.06% |
| Dec 31, 2023 | 99.16% |
| Sep 30, 2023 | 14,205.04% |
| Jun 30, 2023 | -23,372.05% |
| Mar 31, 2023 | -9.00% |